Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Sales of Investments

Cash received from selling or redeeming investments.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments turns negative

Q3 FY2026 sales of investments was -$23.87M, compared with $61.5M a year earlier. Trailing-twelve-month sales of investments was $283.78M. Over 3 fiscal years it compounded at -3.9% a year.

Context

  • Sales of investments amounted to 133.0% of revenue in FY2025, down 67.2 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near -$23.87M or moves back toward the trailing-twelve-month quarterly average of $70.94M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$23.87M-115.2% QoQ
Last fiscal yearDec 2025
$252.47M-3.1% YoY
LTMSep 2026
$283.78M-1.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-138.8%——
1 year-3.1%——
3-year CAGR-3.9%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
252.47M USD
Year-over-year change
-3.1%
4-year CAGR
-8.6%

Sales of Investments vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 sales of investments of $283.78M is the 5th largest of the 11 companies compared; the peer median is $181.22M.
  • Its year-over-year change of -1.6% is the 5th highest of 6, against a peer median of +47.0%.
  • Sales of investments amounts to 101.1% of revenue for RYTM, versus a peer median of 237.5%.
RYTM Competitors Peer median
Sales of Investments for RYTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$767.32B +170746.3%-18.3%74.7%
GPCRStructure Therapeutics Inc.LTM Jun 2026$765.04M +47.0%+117.2%—
VKTXViking Therapeutics, Inc.LTM Jun 2026$478.01M -22.3%+62.7%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$291.5M +36.0%+207.1%—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$283.78M -1.6%-3.9%101.1%
SEPNSepterna, Inc.LTM Sep 2026$268.7M +47.4%—279.1%
BIOABioAge Labs, Inc.LTM Mar 2026$93.74M ——908.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$47.5M ——237.5%
BLTEBelite Bio, IncLTM Jun 2026$52.68K ———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 ———
PTNPalatin Technologies, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding RYTM) $181.22M+47.0%+90.0%237.5%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
Deferred Income Tax(100M)0000
Stock-Based Compensation20.8M19.83M32.55M39.68M66.82M
Change in Working Capital1.9M(19.72M)4.81M10.58M(968K)
Accounts Receivables(1.25M)(5.2M)(8.64M)(3.65M)(7.57M)
Inventory(11K)(2.81M)(5.71M)(10.12M)(7.47M)
Accounts Payables18.31M1.54M14.77M21.92M21.89M
Other Working Capital(15.15M)(13.26M)4.38M2.42M(7.82M)
Other Non-Cash Items(250K)5.91M9.4M94.9M13.68M
Operating Cash Flow(146M)(173.43M)(136.16M)(113.88M)(115.68M)
Capital Expenditures(5.43M)(4.28M)(47K)0(953K)
Acquisitions (Net)100M4M000
Purchases of Investments(524.97M)(251.94M)(354.92M)(268.31M)(348.67M)
Sales of Investments361.25M284.25M354.97M260.64M252.47M
Other Investing Activities7M(4M)(5.67M)(40.5M)(40M)
Investing Cash Flow(62.16M)28.03M(5.67M)(48.17M)(137.15M)
Debt Repayment000(12.9M)0
Common Stock Issued161.73M131.11M48.88M195.24M237.88M
Common Stock Repurchased00000
Dividends Paid000(3.97M)0
Other Financing Activities4.76M82.72M25.49M12.87M(19.92M)
Financing Cash Flow166.48M213.83M74.37M191.24M217.96M
Effect of Forex Changes00(142K)2K87K
Net Change in Cash(41.68M)68.43M(67.6M)29.19M(34.78M)
Free Cash Flow(151.44M)(177.71M)(136.2M)(113.88M)(116.63M)

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.